Biologics

Mark Mikhael, MD, is studying the use of proteins from donor stem cells in spinal fusion surgery, Chicago Health reports.

Market analysts predict the spine biologics market will top $2.6 billion by 2022, growing at a 4.4 percent compound annual growth rate, according to a Market Research Engine report.

SpinalCyte received a U.S. patent for its cartilage repair technology using an in vivo bioreactor.

While the use of biologics in spine surgery is still emerging, more spine surgeons are gaining exposure to the field as new clinical trials and noninvasive treatments are born.

InVivo Therapeutics released the 12-month results of its investigational study of the Neuro-Spinal Scaffold to treat acute thoracic complete spinal cord injury.

Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis.

Isto Biologics is an orthobiologics company that develops spine and orthopedic solutions.

Axial spondyloarthritis patients who received biologics-based treatment had less work and activity impairment than patients who did not receive biologics, according to a study in the Annals of the Rheumatic Diseases.

Dr. Jonathan Hopper joined Vericel Corp., as the company's new CMO.

The global spine biologics market is expected to grow at a 4.4 percent compound annual growth rate to reach more than $2.6 billion by 2022, according to a Market Research Engine report.